- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05812391
Impact of Full Mouth Erythritol Powder Air Polishing on Systemic Inflammatory Response
Systemic Inflammatory Response Following Full Mouth Erythritol Powder Air Polishing and Instrumentation: A Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Periodontitis is a common chronic inflammatory disease caused by specific oral dysbiosis and characterized by a progressive loss of soft and hard tissues keeping the teeth. if left untreated, it leads not only to tooth loss, negative influences on the patient's quality of life and masticatory impairment may happen. There is significant evidence of clinical improvements in PD patients following non-surgical periodontal treatment (NSPT), including gains in clinical attachment level, reductions in gingival inflammation, and reduced periodontal pocket depths.
A conventional Full-mouth hand debridement has been consistently shown to trigger a large systemic inflammatory mediator, The reasons for such a response may be related to both the transient post-operative bacteremia and the extension of the operative trauma.
a recent joint consensus statement advised against full-mouth debridement for some medically compromised patients.
The erythritol powder is a water-soluble, non-toxic sugar alcohol and artificial sweetener, has a mean particle size of 14 μm, and can be used for supra and subgingival removal of biofilm and stains.
It has also been suggested that teeth with sites of furcation involvement and/or with reduced access, which have traditionally been difficult to debride with conventional instrumentation, may benefit from air-flow therapy
Comparing full-mouth ultrasonic debridement with polishing paste and full-mouth erythritol powder air polishing followed by ultrasonic debridement. this study hypothesized that the later procedure may reduce the extent of systemic inflammatory mediators they induce by removing the biofilm before the conventional full-mouth (supra and sub-gingival) ultrasonic debridement.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Baghdad, Iraq, 10053
- Mohammed Kalid Ayoob
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants who have periodontitis, unstable, at any stage
Exclusion Criteria:
- Participants who are known or suspected high risk for tuberculosis
- Participants who have hepatitis B or HIV infections
- Participants who are being unable to provide written, informed consent
- Participants who have history of bleeding diathesis
- Participants who are pregnant or intended to and lactating mother.
- Participants who are self-reported diagnosis of any systemic illnesses including cardiovascular, renal and liver diseases
- Participants who have regular use of medication to control systemic illness.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: test group
Supra-gingival erythritol powerder air polishing Sub-gingival erythritol powerder air polishing Supra-gingival debridement Sub-gingival debridement
|
the treatment start with supra-gingival erythritol powerder air polishing followed by sub-gingival erythritol powerder air polishing,supra-gingival debridement and sub-gingival debridement
|
|
Active Comparator: conventional group
Supra-gingival debridement Sub-gingival debridement Polishing with polishing paste
|
the treatment start with supra-gingival debridement followed by sub-gingival debridement then finished with polishing paste
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in serum level of C-reactive protein
Time Frame: 24 hours
|
Change in serum level of C-reactive protein 24 hours following the full mouth debridement
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment time
Time Frame: 30 days
|
Evaluate the effect of treatment time (minute) on clinical parameters after 30 days
|
30 days
|
|
Change in percentage of bleeding on probing
Time Frame: 30 days
|
Change in the percentage of bleeding on probing 30 days after treatment
|
30 days
|
|
Change in mean probing pocket depth
Time Frame: 30 days
|
Change in mean probing pocket depth (mm) 30 days after treatment
|
30 days
|
|
Change in clinical attachment loss
Time Frame: 30 days
|
Change in clinical attachment loss (mm)30 days after treatment
|
30 days
|
|
Change in percentage of plaque index
Time Frame: 30 days
|
Change in percentage of plaque index 30 days after treatment
|
30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mohammed K Ayoob, University of Baghdad
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 745622
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Periodontal Diseases
-
Tel Aviv UniversityRecruitingPeriodontal Disease | Periodontal Attachment Loss | Periodontal PocketsIsrael
-
Riga Stradins UniversityUniversity of TurkuRecruitingPeriodontitis | Periodontal Diseases | Periodontal Bone Loss | Periodontal Disease | Periodontal Regeneration | Periodontal Healing | Periodontal Granulation Tissue | Vertical Periodontal Bone DefectsLatvia
-
Saglik Bilimleri UniversitesiRecruitingPeriodontitis | Periodontal Diseases | Periodontal Bone Loss | Intrabony Periodontal Defect | Periodontal DefectTurkey (Türkiye)
-
G. d'Annunzio UniversityRecruitingPeriodontal Diseases | Intrabony Periodontal Defect | Periodontal Attachment Loss | Pocket, PeriodontalAlbania
-
Siddharth ShanbhagUniversidad Complutense de MadridNot yet recruitingPeriodontal Disease | Intrabony Periodontal DefectsNorway, Spain
-
Kafrelsheikh UniversityActive, not recruitingPeriodontal Diseases | Periodontal Attachment LossEgypt
-
Ohio State UniversityNot yet recruitingPeriodontal Disease | Periodontal SurgeryUnited States
-
Krishnadevaraya College of Dental Sciences & HospitalCompletedPeriodontitis | Periodontal Attachment Loss | Periodontal Inflammation | Pocket, PeriodontalIndia
-
University of Roma La SapienzaActive, not recruitingPeriodontal Disease | Periodontal Disease, AVDC Stage 3 | Periodontal Disease Stage 2Italy
-
University of BeykentCompletedPeriodontal Diseases | Periodontal Attachment Loss | Periodontal Inflammation | Periodontal Disease, AVDC Stage 3 | Periodontal Disease, AVDC Stage 4Turkey
Clinical Trials on test
-
Centre Hospitalier Universitaire de Saint EtienneRecruitingInfantile Spinal Muscular Atrophy | Spinal Amyotrophy | Juvenile Spinal Muscular AtrophyFrance
-
Groupe Hospitalier Mutualiste de GrenobleFondation de l'AvenirCompleted
-
Recep Tayyip Erdogan University Training and Research...Completed
-
Yonsei UniversityCompletedPostprandial Hyperglycemia
-
University of FloridaCompletedParkinson Disease (PD)United States
-
Clinical Nutrition Research Centre, SingaporeCompleted
-
University of MichiganCompletedAntidepressants Causing Adverse Effects in Therapeutic UseUnited States
-
University of BaghdadCompletedSexual Behavior | Sexual Orientation Conflict Disorder | Sexual Arousal Disorder | Sexual Orientation | Sexual; Orientation, Relationship DisorderIraq
-
M.D. Anderson Cancer CenterUnknownLung CancerUnited States